October 14, 2026 BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
September 29, 2026 BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
September 17, 2026 BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
September 14, 2026 BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
August 31, 2026 BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
August 28, 2026 BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
August 24, 2026 BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
